Nektar Therapeutics (NKTR) Expected to Announce Earnings on Monday

Nektar Therapeutics (NASDAQ:NKTR) is expected to post its quarterly earnings results before the market opens on Monday, March 3rd. Analysts expect Nektar Therapeutics to post earnings of ($0.18) per share and revenue of $36.65 million for the quarter.

Nektar Therapeutics Stock Up 5.9 %

NKTR opened at $0.84 on Friday. The firm has a market capitalization of $155.50 million, a P/E ratio of -1.00 and a beta of 0.58. The stock has a fifty day moving average of $0.90 and a 200-day moving average of $1.11. Nektar Therapeutics has a 12-month low of $0.65 and a 12-month high of $1.93.

Wall Street Analysts Forecast Growth

NKTR has been the subject of several research analyst reports. William Blair reissued a “market perform” rating on shares of Nektar Therapeutics in a research note on Tuesday. Piper Sandler began coverage on shares of Nektar Therapeutics in a report on Monday, November 4th. They set an “overweight” rating and a $7.00 price target for the company. HC Wainwright reaffirmed a “buy” rating and set a $6.50 price objective on shares of Nektar Therapeutics in a research report on Tuesday. Finally, B. Riley assumed coverage on shares of Nektar Therapeutics in a research report on Wednesday, January 8th. They issued a “buy” rating and a $4.00 target price for the company. Two research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $4.08.

Insider Buying and Selling

In other news, insider Jonathan Zalevsky sold 51,115 shares of the stock in a transaction on Thursday, December 19th. The shares were sold at an average price of $0.94, for a total transaction of $48,048.10. Following the transaction, the insider now owns 326,904 shares in the company, valued at $307,289.76. This represents a 13.52 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Howard W. Robin sold 46,995 shares of the firm’s stock in a transaction on Tuesday, December 17th. The shares were sold at an average price of $1.01, for a total transaction of $47,464.95. Following the transaction, the chief executive officer now owns 1,195,710 shares in the company, valued at $1,207,667.10. This represents a 3.78 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 165,586 shares of company stock worth $159,990. Insiders own 3.71% of the company’s stock.

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.